sisupakettide

Sisupakettide is a monoclonal antibody used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. It is administered through intravenous infusion and works by targeting and destroying cancer cells. The drug is part of a class of therapies known as proteasome inhibitors, which interfere with the production of proteins essential for cancer cell survival.

Sisupakettide was approved by the U.S. Food and Drug Administration (FDA) in 2019 for the treatment of relapsed or refractory multiple myeloma. It is often used in combination with other therapies, such as dexamethasone and lenalidomide, to improve treatment outcomes. The drug is typically administered every two weeks.

Common side effects of sisupakettide include peripheral neuropathy, which can cause numbness or tingling in the hands and feet, and fatigue. More serious side effects may include infections, low blood cell counts, and gastrointestinal issues. Patients should be closely monitored for these potential side effects during treatment.

Sisupakettide is manufactured by Takeda Pharmaceutical Company Limited. The drug is available under the brand name Kyprolis. It is prescribed by healthcare professionals based on individual patient characteristics and treatment goals.